CURRICULUM VITAE

Full Name:	Rodriguez	Miguel	D
	Last Name	First Name	Middle Initial

Professional Mailing Address: (Include institution name.)

IMIC, Inc,
18320 SW 97 Ave (aka 18320 Franjo Rd)
Palmetto Bay FL 33157

Telephone: 786-310-7477/ fax 786-536-9016, email: miguel@aktamedika.com

Academic Qualifications (most current date first)

Degree/Certification	Date (YYYY)	Institution, Country
GCP	2016	CITI, Miami FL USA
Fellow Gastroenterology and internal medicine Specialist	1999 1995	American College of Gastroenterology, USA American Board of Internal Medicine, USA
Fellowship Hepatology	1993-1994	UMDNJ University Hospital, USA
Fellowship Gastroenterology	1990-1992	J Dempsey Hospital University, USA
Residency internal medicine	1985-1989	Harlem Hospital Center RM, USA
MD	1975-1983	Universidad Nacional Pedro Henriquez Urena, Santo Domingo, Dominican Republic

Current and Previous 4 Relevant Positions Including Academic Appointments (most current date first):

Start and End Dates	Title	Institution or Company, State/Province/Country
2013-current	PI, Sub Investigator	IMIC, Inc.
1995-current	Gastroenterologist	Miami Gastroenterology Consultants, Miami FL USA

Brief Summary of Relevant Clinical Research Experience in the last 10 years:

Participation in 29 Clinical studies as SI and PI in trials phase 2, 3 and 4 in cirrhosis, constipation, Crohn's disease and Ulcerative colitis.

Detailed description of studies in last 3 years:

2017-IDN-6556-17: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects with Decompensated Non-Alcoholic Steatohepatitis (NASH) Cirrhosis as PI

2017-Protocol No. GS-US-384-1944: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH) as PI

2016-E5501-G000-310: A Randomized, Global, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Once-daily Oral Avatrombopag for the Treatment of Adults with Thrombocytopenia Associated with Liver Disease Prior to an Elective Procedure as PI

2017- GS-US-384-1943: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis as PI

2016 - RPC01-3102:A Phase 3, Multicenter, Open-Label Extension Trial of Oral RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis as PI

2016 - IDN-6556-14: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects with Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension as PI

2016 - A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF GED-0507-34-LEVO (GED0507) FOR TREATMENT OF SUBJECTS WITH ACTIVE ULCERATIVE COLITIS, GED0507-UC-001 as PI

2016 - BLI400-303: An Open Label Study of Chronic Use of BLI400 Laxative in Constipated Adults as PI

2016 - GA28951: AN OPEN-LABEL EXTENSION AND SAFETY MONITORING STUDY OF MODERATE TO SEVERE ULCERATIVE COLITIS PATIENTS PREVIOUSLY ENROLLED IN ETROLIZUMAB PHASE III STUDIES as PI

2015 - 000175 -A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Investigating the Efficacy and Safety of Mesalamine 2 g Extended Release Granules (Sachet) for Maintenance of Clinical and Endoscopic Remission in Ulcerative Colitis as PI

2015 - M13-740 -A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects with Moderately to Severely Active Crohn's Disease who have Inadequately Responded to or are Intolerant to Anti-TNF Therapy as PI

2015 - RPC01-3101: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Oral RPC1063 as Induction and Maintenance Therapy for Moderate to Severe Ulcerative Colitis as PI

2015 - RPC01-2201: A Phase 2, Multi-Center, Open-Label Induction Trial with Extension Period to Assess Endoscopic Improvement and Changes in Intestinal and Serum Biomarkers in Patients with Moderately to Severely Active Crohn's Disease Receiving Oral RPC1063 as Induction Therapy as PI

2015 - 000174 - A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Investigating the Efficacy and Safety of Mesalamine 4 g Extended Release Granules (Sachet) for the Induction of Clinical and Endoscopic Remission in Active, Mild to Moderate Ulcerative Colitis as PI

2015 - SP333101-04, A Phase 1b, Exploratory, Double Blind, Placebo-Controlled Four-Week Study of Rectally Administered SP-333 for the Treatment of Patients with Mildly to Moderately Active Left-Sided Ulcerative Colitis as PI

2015 -ga29102- PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY (MAINTENANCE OF REMISSION) AND SAFETY OF ETROLIZUMAB COMPARED WITH PLACEBO IN PATIENTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS WHO ARE NAIVE TO TNF INHIBITORS as PI

2015 - A Randomized, Double-Blind, Placebo-Controlled Evaluation of MF4637 for Correcting the Omega-3 Nutritional Deficiency in NAFLD Patients When Added to Standard of Care as PI

2015 - Protocol number:D5170C00002. Protocol title: A Phase 2b Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects with Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti Tumor Necrosis Factor-Alpha Therapy as PI

2015 - BLI400-301 - A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adults as PI

2015 - GT-026: A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients with NASH Cirrhosis. The NASH-CX

Trial as PI

2015- GA29144 - A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ETROLIZUMAB AS AN INDUCTION AND MAINTENANCE TREATMENT FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE as PI

2015- GA29145: AN OPEN-LABEL EXTENSION AND SAFETY MONITORING STUDY OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE PREVIOUSLY ENROLLED IN THE ETROLIZUMAB PHASE III PROTOCOL GA29144 as PI

2014- A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF RIFAXIMIN SOLUBLE SOLID DISPERSION (SSD) TABLETS FOR THE PREVENTION OF COMPLICATIONS IN SUBJECTS WITH EARLY DECOMPENSATED LIVER CIRRHOSIS as SI

2014 - A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional Study to Assess the Efficacy (Symptomatic and Endoscopic Improvement) and Safety of Rifaximin Delayed Release Tablets for the Induction of Remission and Prevention of Relapse in Subjects with Active Moderate Crohn's Disease as PI

2014- A National, Randomized, 12-Week, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Plecanatide (3.0 and 6.0 mg) in Patients with Chronic Idiopathic Constipation as SI

2014 - A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Naldemedine in the Treatment of Opioid-induced Constipation in Subjects with Non-malignant Chronic Pain Receiving Opioid Therapy as SI

2013- A Randomized, 4-Week, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of SP-333 for the Treatment of Opioid-induced Constipation (OIC) in Patients with Non-malignant Chronic Pain Receiving Opioid Therapy as SI

License # ME68746/FL	Expiring 01/31/2019	FL/USA	

Signature: 	**Signature Date:** 12-April-2017